Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone†or “the Companyâ€), a clinical-stage biotechnology company focused…